XML 362 R35.htm IDEA: XBRL DOCUMENT
v3.26.1

Segment information (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Segment information |
Summary of segment information | The segment information for the financial year 2025 is as follows:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | Discovery & | ​ ​ ​ | ​ | ​ ​ ​ | ​ | ​ ​ ​ | ​
​ | ​ ​ ​ | Preclinical | ​ ​ ​ | Just - Evotec | ​ ​ ​ | Intersegment | ​ ​ ​ | Evotec
in k€ | ​ | Development | ​ | Biologics | ​ | eliminations | ​ | Group
Revenue* |  | 528,930 |  | 259,443 |  | — |  | 788,373
Intersegment revenue | ​ | 352 | ​ | 144 | ​ | (496) | ​ | —
Cost of revenue | ​ | (482,470) | ​ | (192,161) | ​ | 479 | ​ | (674,152)
Gross profit | ​ | 46,811 | ​ | 67,426 | ​ | (17) | ​ | 114,221
Operating income and (expenses) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Research and development | ​ | (37,454) | ​ | (72) | ​ | 17 | ​ | (37,509)
Selling, general and administrative expenses | ​ | (133,248) | ​ | (42,722) | ​ | — | ​ | (175,970)
Other operating income | ​ | 61,370 | ​ | 4,230 | ​ | — | ​ | 65,599
Other operating expenses | ​ | (11,327) | ​ | (10,597) | ​ | — | ​ | (21,924)
Reorganization costs | ​ | (633) | ​ | — | ​ | — | ​ | (633)
Total operating income (expenses) | ​ | (121,294) | ​ | (49,161) | ​ | 17 | ​ | (170,438)
Operating income (loss)** |  | (74,482) |  | 18,265 |  | — |  | (56,217)
*Includes Revenue from contributions of €11,294k **Includes €65,291k of depreciation and €9,478k of amortization related to D&PD and includes €24,707k of depreciation and €-k of amortization related to JEB The segment information for the financial year 2024 is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Discovery & | ​ ​ ​ | ​ | ​ ​ ​ | ​ | ​ | ​
​ | ​ | Preclinical | ​ | Just - Evotec | ​ | Intersegment | ​ | Evotec
in k€ | ​ ​ ​ | Development | ​ ​ ​ | Biologics | ​ ​ ​ | eliminations | ​ ​ ​ | Group
Revenue* | ​ | 611,394 |  | 185,573 |  | — |  | 796,967
Intersegment revenue |  | 160 | ​ | 1,049 | ​ | (1,208) | ​ | —
Cost of revenue | ​ | (509,361) | ​ | (173,068) | ​ | 344 | ​ | (682,086)
Gross profit | ​ | 102,192 | ​ | 13,553 | ​ | (865) | ​ | 114,881
Operating income and (expenses) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Research and development | ​ | (51,146) | ​ | (576) | ​ | 865 | ​ | (50,857)
Selling, general and administrative expenses | ​ | (158,915) | ​ | (29,286) | ​ | — | ​ | (188,201)
Other operating income | ​ | 49,802 | ​ | 2,899 | ​ | — | ​ | 52,700
Other operating expenses | ​ | (13,924) | ​ | (2,192) | ​ | — | ​ | (16,116)
Reorganization costs | ​ | (54,179) | ​ | (751) | ​ | — | ​ | (54,930)
Total operating income (expenses) | ​ | (228,362) | ​ | (29,906) | ​ | 865 | ​ | (257,403)
Operating income (loss)** | ​ | (126,170) |  | (16,353) |  | — |  | (142,522)
*Includes Revenue from contributions of €14,450k **Includes €70,753k of depreciation and €6,484k of amortization related to D&PD and includes €24,404k of depreciation and €-k of amortization related to JEB The segment information for the financial year 2023 is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | Discovery & | ​ ​ ​ | ​ | ​ ​ ​ | ​ | ​ ​ ​ | ​
​ | ​ | Preclinical | ​ | Just - Evotec | ​ | Intersegment | ​ | Evotec
in k€ | ​ ​ ​ | Development | ​ ​ ​ | Biologics | ​ ​ ​ | eliminations | ​ ​ ​ | Group
Revenue* | ​ | 672,977 | ​ | 108,449 | ​ | — | ​ | 781,426
Intersegment revenue | ​ | — |  | — |  | — | ​ | —
Cost of revenue | ​ | (492,674) | ​ | (113,701) | ​ | — | ​ | (606,375)
Gross profit | ​ | 180,303 | ​ | (5,252) | ​ | — | ​ | 175,051
Operating income and (expenses) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Research and development | ​ | (68,529) | ​ | — | ​ | — | ​ | (68,529)
Selling, general and administrative expenses | ​ | (143,167) | ​ | (26,442) | ​ | — | ​ | (169,610)
Impairment/Reversal of impairment of intangible assets | ​ | 108 | ​ | (5,119) | ​ | — | ​ | (5,011)
Other operating income | ​ | 62,524 | ​ | 2,269 | ​ | — | ​ | 64,793
Other operating expenses | ​ | (39,361) | ​ | (4,841) | ​ | — | ​ | (44,202)
Reorganization costs | ​ | — | ​ | — | ​ | — | ​ | —
Total operating income (expenses) | ​ | (188,425) | ​ | (34,133) | ​ | — | ​ | (222,558)
Operating income (loss)** | ​ | (8,122) | ​ | (39,385) | ​ | — | ​ | (47,507)
*Includes Revenue from contributions of €9,417k **Includes €64,349k of depreciation and €6,946k of amortization related to D&PD and includes €21,685k of depreciation and €-k of amortization related to JEB
Summary of geographical breakdown | The geographical breakdown of revenue from customers for the financial year 2025 is stated below:
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Discovery & | ​ | ​ | ​ | ​
​ | ​ | Preclinical | ​ | Just - Evotec | ​ | ​
in k€ | ​ ​ ​ | Development | ​ ​ ​ | Biologics | ​ ​ ​ | Evotec Group
Revenue by region |  | ​ |  | ​ |  | ​
USA |  | 323,508 |  | 108,001 |  | 431,509
Germany |  | 25,293 |  | — |  | 25,293
France |  | 19,783 |  | 72 |  | 19,855
United Kingdom |  | 61,724 |  | — |  | 61,724
Switzerland |  | 10,892 |  | 150,721 |  | 161,613
Rest of the world |  | 76,436 |  | 649 |  | 77,085
Total revenue from contracts with customers | ​ | 517,636 | ​ | 259,443 | ​ | 777,079
Revenue from contributions | ​ | 11,294 | ​ | — | ​ | 11,294
Total Revenue |  | 528,930 |  | 259,443 |  | 788,373
​ ​ The geographical breakdown of revenue from customers for the financial year 2024 is stated below: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Discovery & | ​ | ​ | ​ | ​
​ | ​ | Preclinical | ​ | Just - Evotec | ​ | ​
in k€ | ​ ​ ​ | Development | ​ ​ ​ | Biologics | ​ ​ ​ | Evotec Group
Revenue by region |  | ​ |  | ​ |  | ​
USA |  | 354,124 |  | 91,735 |  | 445,859
Germany |  | 32,904 |  | — |  | 32,904
France |  | 19,910 |  | — |  | 19,910
United Kingdom |  | 92,437 |  | 80 |  | 92,517
Switzerland |  | 18,048 |  | 90,995 |  | 109,043
Rest of the world |  | 81,662 |  | 621 |  | 82,283
Total revenue from contracts with customers | ​ | 599,086 | ​ | 183,431 | ​ | 782,517
Revenue from contributions | ​ | 12,308 | ​ | 2,142 | ​ | 14,450
Total Revenue |  | 611,394 |  | 185,573 |  | 796,967
​ The geographical breakdown of revenue from customers for the financial year 2023 is stated below:
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Discovery & | ​ | ​ | ​ | ​
​ | ​ | Preclinical | ​ | Just - Evotec | ​ | ​
in k€ | ​ ​ ​ | Development | ​ ​ ​ | Biologics | ​ ​ ​ | Evotec Group
Revenue by region |  | ​ |  | ​ |  | ​
USA |  | 414,192 |  | 45,232 |  | 459,424
Germany |  | 29,297 |  | 4,837 |  | 34,134
France |  | 32,005 |  | — |  | 32,005
United Kingdom |  | 86,368 |  | — |  | 86,368
Switzerland |  | 7,500 |  | 57,424 |  | 64,924
Rest of the world |  | 95,154 |  | — |  | 95,154
Total revenue from contracts with customers | ​ | 664,516 |  | 107,493 |  | 772,009
Revenue from contributions | ​ | 8,461 | ​ | 956 | ​ | 9,417
Total Revenue |  | 672,977 |  | 108,449 |  | 781,426
Non-current assets categorized by the location of the companies as of December 31, 2025 and December 31, 2024 can be analyzed as follows:
​ | ​ | ​ | ​ | ​
in k€ | ​ ​ ​ | 2025 | ​ ​ ​ | 2024
USA |  | 216,421 |  | 257,861
United Kingdom |  | 180,577 |  | 208,907
Italy |  | 230,258 |  | 240,450
France |  | 89,704 |  | 325,974
Germany |  | 188,451 |  | 154,543
Total non-current assets |  | 905,411 |  | 1,187,735

X
- Definition Represent of Disclosure Of Operating Segment + References No definition available. + Details
Name: | evo_DisclosureOfOperatingSegmentAbstract
Namespace Prefix: | evo_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2025-01-01 -Section Disclosure -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of geographical information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2025-01-01 -Paragraph 33 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfGeographicalAreasExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration